The European Commission has granted an expanded approval to ravulizumab-cwvz to include children with a body weight of at least 10 kg, as well as adolescents, with paroxysmal nocturnal hemoglobinuria.
American Cancer Society
Latest Content
For most of the pandemic, COVID-19 has been mild in children. Has this been true for children with underlying health conditions, in particular cancer?
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
Transforming teen obesity care: How integrated specialty pharmacy models expand GLP-1 access
2
Redefining type 1 diabetes: Early identification, staging, and clinical implications for pediatric care
3
Daniele De Luca, MD, discusses zelpultide alfa in neonates at high risk of bronchopulmonary dysplasia development
4
CDC updates website, opens door for autism and vaccines link
5
